Vivos Therapeutics (VVOS) had its price target lowered by Ascendiant Capital Markets from $5.50 to $3.00. They now have a "buy" rating on the stock.
Vivos Therapeutics (VVOS) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Vivos Therapeutics (VVOS) had its price target lowered by HC Wainwright from $7.00 to $2.50. They now have a "buy" rating on the stock.
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... [Yahoo! Finance]
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call [Yahoo! Finance]